Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Single or Multiple Applications of StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects

NCT03005054 is registered in ClinicalTrials.gov with Stratatech, a Mallinckrodt Company as lead sponsor.

NCT NCT03005054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03005054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Single or Multiple Applications of StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects
Lead sponsor
Stratatech, a Mallinckrodt Company
Phase
Phase 2
Overall status
Terminated
Start date
April 24, 2017
Completion date
March 26, 2019
Enrollment
3 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

burns, skin wound, trauma-related wound